Advanced Biomed Inc

Advanced Biomed Inc(ADVB)股票分析

$3.980

-0.734 (-18.44%)收盤時

Loading chart…
最高
4.700
開盤
4.690
成交量加權均價
4.12
成交量
28.28K
市值
—
最低
3.694
成交金額
116.63K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip.

AI 分析 of Advanced Biomed Inc (ADVB)

賣出

Given the current price of $3.98, a significantly low RSI of 7.381 indicates extreme overselling, but the recent 5-day change of -25.05% and a 1-year change of -53.92% suggest that the stock is in a downward trend. The risk of continued losses is high, especially with a negative forward P/E ratio of 0 and a price-to-sales ratio of 63.17, indicating overvaluation compared to sales. Therefore, it is not a good buy right now.

估值指標

Advanced Biomed Inc(ADVB)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.00
目前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 對 ADVB 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ADVB

$0.72

情境價格

基

基準

基準 · 50%ADVB

$0.61

情境價格

悲

悲觀

悲觀 · 25%ADVB

$0.56

情境價格

事件時間軸

2026-07-30 (ET)

10:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-27 (ET)

10:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-24 (ET)

11:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-23 (ET)

10:30:00

Advanced Biomed Inc Trading Halted Due to Volatility

2026-07-22 (ET)

10:00:00

Advanced Biomed Inc Trading Halted Due to Volatility

資訊

ADVB 常見問題 —— 由 Alphio AI 解答

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip. It operates in the Healthcare sector.

Given the current price of $3.98, a significantly low RSI of 7.381 indicates extreme overselling, but the recent 5-day change of -25.05% and a 1-year change of -53.92% suggest that the stock is in a downward trend. The risk of continued losses is high, especially with a negative forward P/E ratio of 0 and a price-to-sales ratio of 63.17, indicating overvaluation compared to sales. Therefore, it is not a good buy right now.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易